In today’s competitive CGM market, the race to communicate product value is accelerating. As marketing efforts intensify, the boundary between compelling messaging and overstatement can quickly become blurred. Ensuring that promotional claims remain accurate and defensible require more than strong communication, it demands a solid foundation in clinical evidence.

Clinical Affairs is often assumed to play a limited role once the clinical study report (CSR) is complete. In practice, the opposite is true. The completion of the CSR marks the beginning of a critical phase in which clinical data must be translated into external messaging. Under tight timelines, marketing teams must develop materials for clinicians, patients, and policymakers. Without proper oversight, claims can unintentionally exceed what the data supports. Clinical Affairs serves as a safeguard in this process, ensuring that messaging remains scientifically grounded and compliant.

The review workflow

Although processes vary across organizations, promotional review is consistently driven by three priorities: accuracy, efficiency, and compliance. To avoid delays and costly revisions, materials should enter review with complete citations and minimal errors. Clinical Affairs evaluates whether claims are supported by robust evidence and whether they accurately reflect study findings.

This review involves several key steps. Each claim is assessed against the underlying data. Citations are verified for accuracy and proper alignment. Data presentation is evaluated to ensure it is balanced and not selectively emphasized. Supporting studies are reviewed for credibility, relevance, and timeliness. Just as importantly, conclusions must reflect both the strengths and limitations of the evidence.

Partnership with regulatory affairs

Clinical Affairs works in close alignment with Regulatory Affairs to ensure that promotional messaging meets both scientific and regulatory expectations. This collaboration includes reviewing claim matrices, confirming consistency with approved labeling, and staying current with evolving regulatory standards. Their combined oversight ensures that claims are not only accurate, but also defensible in a regulatory context.

Balancing creativity with scientific integrity

Marketing teams are tasked with highlighting meaningful product advantages. However, without appropriate guardrails, this effort can lead to overgeneralization of the data. Clinical Affairs ensures that claims are consistent with study design, patient populations, and endpoints. It prevents exploratory findings from being presented as confirmed outcomes. It also limits the generalization of subgroup analyses beyond their intended scope. When comparative claims are made, it verifies that they are supported by appropriate evidence. This oversight keeps messaging impactful while grounded in evidence.

Avoiding overgeneralization of clinical data

Overgeneralization remains a common challenge in CGM promotion. Claims are sometimes extended beyond the populations or endpoints originally studied.

For example, a statement such as 'Our CGM significantly improves glycemic control for all users' may be derived from a limited study population. Clinical Affairs ensures this language is revised to reflect the evidence accurately. Broader claims require additional supporting data, such as studies including diverse populations.

In this scenario, Clinical Affairs would require the claim to be revised to accurately reflect the study population and outcomes, such as: “Our CGM demonstrated significant improvements in HbA1c levels in adults with type 1 diabetes.” If marketing insists on making a broader claim applicable to all patients, Clinical Affairs may recommend additional clinical or real-world evidence that includes pediatric populations and individuals with type 2 diabetes. With sufficient supporting data, an appropriate revised claim might read: “Our CGM demonstrated significant improvements in HbA1c levels in adult and pediatric patients.”

This approach ensures scientific accuracy while still enabling marketing to communicate a meaningful and defensible benefit.

Digital and social media promotional materials

Digital platforms introduce added complexity, particularly with influencer content and patient testimonials. These formats can blur the distinction between personal experience and promotional messaging.

A common mistake occurs when influencers describe individual outcomes in ways that suggest guaranteed or universal benefits. For example, an influencer may state that using a CGM “gave me complete control over my blood sugars.” Although such statement reflects personal experiences, they can be misleading for several reasons. First, CGM systems measure glucose levels in interstitial fluid rather than blood, which can differ from capillary blood glucose values, particularly during periods of rapid glucose change (Siegmund, 2017).

Second, CGM use represents only one component of diabetes management. Glycemic outcomes are also influenced by factors such as medication use, dietary patterns, physical activity, and individual physiology (ADA, 2018).

Clinical Affairs reviews content to ensure that personal narratives do not imply universal outcomes and that messaging remains accurate and compliant. Because patient stories strongly influence decision-making, ensuring accuracy in these communications is especially critical.

Conclusion

Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By bridging clinical data, regulatory expectations, and marketing objectives, it enables responsible communication without compromising integrity.

As the CGM landscape evolves, integrating Clinical Affairs early in promotional development strengthens credibility, supports informed decisions, and ultimately benefits patient care.

Sources

1. American Diabetes Association. (2018, April). Good to Know: Factors affecting blood glucose. Clinical Diabetes, 36(2), 202. https://doi.org/10.2337/cd18-0012
2. Siegmund, T., Heinemann, L., Kolassa, R., & Thomas, A. (2017). Discrepancies between blood glucose and interstitial glucose—Technological artifacts or physiology: Implications for selection of the appropriate therapeutic target. Journal of Diabetes Science and Technology, 11(4), 766–772. https://doi.org/10.1177/1932296817699637